FDA Inspection
Gland Pharma Limited, Units I+II Pashamylaram SiteGland Pharma Limited, Units I+II Pashamylaram Site – FDA Inspection, Jun 27, 2023
Record Details
This FDA Inspection record concerns Gland Pharma Limited, Units I+II Pashamylaram Site, with an inspection on June 27, 2023, issued by the Center for Drug Evaluation and Research, covering drugs.
- Inspection Date
- June 27, 2023
- Product Type
- Drugs
View Company Profile
ID · cdefda8a-9fac-4c48-90f1-47b5c117ec07
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1210478
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
FDA Citations
1- 21 CFR 211.42(c)(10)(i)Floors, walls, ceiling surfaces
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Gland Pharma Limited, Units I+II Pashamylaram Site
6| Date | Classification | Office | Project area |
|---|---|---|---|
| August 2, 2024 | Not classified | Office of Inspections and Investigations | Drug Quality Assurance |
| August 26, 2023 | VAI | Center for Devices and Radiological Health | Compliance: Devices |
| November 7, 2019 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| May 29, 2018 | Not classified | Office of Inspections and Investigations | |
| February 23, 2018 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Gland Pharma Limited, Units I+II Pashamylaram Site
- FDA Inspection 1244660 - 2024-08-02
- FDA Inspection 1216053 - 2023-08-26
- FDA Inspection 1109239 - 2019-11-07
- FDA Inspection 1057719 - 2018-05-29
- FDA Inspection 1043371 - 2018-02-23
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.